Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 3/20 | 0.50 |
| ▸ | IGF1R | P08069 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.48 |
| ▸ | DRD2 | P14416 | 2/20 | 0.48 |
| ▸ | DRD1 | P21728 | 2/20 | 0.48 |
| ▸ | DRD4 | P21917 | 2/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.48 |
| ▸ | DRD3 | P35462 | 2/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | THPO | P40225 | 2/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29684623 | 1.00 | ALOX15 (0.50) | ALOX15IGF1RKDM4EMAPK1ADRB2 | |
| SCHEMBL15218641 | 0.83 | ADRB2 (0.40) | ADRB2ADRB1 | |
| SCHEMBL29684225 | 0.83 | ADRB2 (0.58) | MAPK1ADRB2LMNASIGMAR1TSHR | |
| SCHEMBL2969158 | 0.83 | ADRB2 (0.58) | MAPK1ADRB2LMNASIGMAR1TSHR | |
| SCHEMBL2970155 | 0.82 | TYR (0.47) | ADRB2LMNAADRA2ASLC6A2ADRA1A | |
| SCHEMBL2970029 | 0.80 | STAT3 (0.57) | ADRB2LMNASLC6A3HIF1ASLC22A1 | |
| SCHEMBL29684134 | 0.80 | STAT3 (0.57) | ADRB2LMNASLC6A3HIF1ASLC22A1 | |
| SCHEMBL2978394 | 0.79 | CALM1 (0.51) | ADRB2CYP3A4NFKB1ALDH1A1 | |
| SCHEMBL13206585 | 0.77 | TYR (0.50) | TAAR1 | |
| SCHEMBL13206584 | 0.77 | TYR (0.50) | TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210085580-A1 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | UNIGEN, INC. (US) | 2021-03-25 | — | — | US | claimed |
| US-20200170907-A1 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | UNIGEN, INC. (US) | 2020-06-04 | — | — | US | claimed |
| US-20160193126-A1 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | UNIGEN INC (US) | 2016-07-07 | — | — | US | claimed |
| EP-1748767-A4 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | UNIGEN PHARMACEUTICALS INC (US) | 2008-12-24 | — | — | EP | claimed |
| US-20080132581-A1 | particularly tyrosinase; preventing and treating melanin overproduction; isolated from a plant family selected from the group consisting of Compositae, Fabaceae, Lauraceae, Leguminosae, Liliaceae, Loranthaceae, Moracea, and Myristicaceae | UNIGEN PHARMACEUTICALS, INC. (US) | 2008-06-05 | — | — | US | claimed |
| EP-1748767-A1 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | Unigen Pharmaceuticals, Inc. (US) | 2007-02-07 | — | — | EP | claimed |
| WO-2005117849-A1 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | UNIGEN PHARMACEUTICALS, INC. (US) | 2005-12-15 | — | — | WO | claimed |
| US-20050267047-A1 | Diarylalkanes as potent inhibitors of binuclear enzymes | UNIGEN PHARMACEUTICALS, INC. (US) | 2005-12-01 | — | — | US | claimed |
| US-11857657-B2 | Diarylalkanes as potent inhibitors of binuclear enzymes | UNIGEN, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11857657-B2 | Diarylalkanes as potent inhibitors of binuclear enzymes | UNIGEN, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11857657-B2 | Diarylalkanes as potent inhibitors of binuclear enzymes | UNIGEN, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| CN-109134205-B | Diarylalkanes as potent inhibitors of binuclear enzymes | 尤尼根公司 | 2022-07-19 | — | — | CN | disclosed |
| US-20210085580-A1 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | UNIGEN, INC. (US) | 2021-03-25 | — | — | US | disclosed |
| US-20210085580-A1 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | UNIGEN, INC. (US) | 2021-03-25 | — | — | US | disclosed |
| US-20080132581-A1 | particularly tyrosinase; preventing and treating melanin overproduction; isolated from a plant family selected from the group consisting of Compositae, Fabaceae, Lauraceae, Leguminosae, Liliaceae, Loranthaceae, Moracea, and Myristicaceae | UNIGEN PHARMACEUTICALS, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080132581-A1 | particularly tyrosinase; preventing and treating melanin overproduction; isolated from a plant family selected from the group consisting of Compositae, Fabaceae, Lauraceae, Leguminosae, Liliaceae, Loranthaceae, Moracea, and Myristicaceae | UNIGEN PHARMACEUTICALS, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080132581-A1 | particularly tyrosinase; preventing and treating melanin overproduction; isolated from a plant family selected from the group consisting of Compositae, Fabaceae, Lauraceae, Leguminosae, Liliaceae, Loranthaceae, Moracea, and Myristicaceae | UNIGEN PHARMACEUTICALS, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| EP-1748767-A1 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | Unigen Pharmaceuticals, Inc. (US) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005117849-A1 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | UNIGEN PHARMACEUTICALS, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050267047-A1 | Diarylalkanes as potent inhibitors of binuclear enzymes | UNIGEN PHARMACEUTICALS, INC. (US) | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200170907-A1 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | TYR, DDT, HAAO | ALOX15 1531/4885IGF1R 4405/4885KDM4E 1642/4885 |
| US-20050267047-A1 | Diarylalkanes as potent inhibitors of binuclear enzymes | TYR, DDT, HAAO | ALOX15 1531/4885IGF1R 4405/4885KDM4E 1642/4885 |
| US-20160193126-A1 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | TYR, DDT, HAAO | ALOX15 1531/4885IGF1R 4405/4885KDM4E 1642/4885 |
| US-20210085580-A1 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | TYR, DDT, HAAO | ALOX15 1531/4885IGF1R 4405/4885KDM4E 1642/4885 |
| US-20080132581-A1 | particularly tyrosinase; preventing and treating melanin overproduction; isolated from a plant family selected from the group consisting of Compositae, Fabaceae, Lauraceae, Leguminosae, Liliaceae, Loranthaceae, Moracea, and Myristicaceae | TYR, MAOA, CYP51A1 | ALOX15 257/4885IGF1R 3465/4885KDM4E 1262/4885 |
| US-11857657-B2 | Diarylalkanes as potent inhibitors of binuclear enzymes | TYR, DDT, HAAO | ALOX15 1531/4885IGF1R 4405/4885KDM4E 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.